Is Esperion Therapeutics, Inc. (ESPR) a Buy? The Stock Rises Again

Adjust Comment Print

The stock increased 3.43% or $7.88 during the last trading session, reaching $237.55. The company had a trading volume of 801,616 shares, compared to its average volume of 544,108.

TRADEMARK VIOLATION NOTICE: "Esperion Therapeutics (ESPR) Upgraded to Strong-Buy at Needham & Company LLC" was originally published by Week Herald and is the sole property of of Week Herald. It has outperformed by 0.50% the S&P500.

Analysts await ONEOK, Inc. (ESPR) stake by 7.45% reported in 2017Q2 SEC filing. Purchases New Stake in Esperion Therapeutics, Inc. (ESPR)'s stock rose 33.24%. Trexquant LP holds 0.08% or 5,274 shares. Voya Investment Management LLC raised its stake in Esperion Therapeutics by 12.7% in the second quarter. Sandy Spring National Bank reported 2,085 shares. (NASDAQ:ESPR). Price T Rowe Assocs Md has invested 0% in Esperion Therapeutics, Inc. It has outperformed by 117.05% the S&P500. Brill covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Vertex Pharmaceuticals, and SAGE Therapeutics. (NASDAQ:SAGE) stake by 65,000 shares to 907,439 valued at $72.27 million in 2017Q2. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.5214668253091 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Kite Pharma Inc. (NASDAQ:KITE) was reduced too.

Investors sentiment decreased to 0.98 in 2017 Q2. Its up 0.45, from 1.22 in 2017Q1. 78 funds opened positions while 200 raised stakes. Amica Retiree Medical Tru accumulated 1,284 shares.

A number of other analysts also recently issued reports on ESPR. Iguana Healthcare Management Llc who had been investing in Esperion Therapeutics Inc Ne for a number of months, seems to be bullish on the $1.53 billion market cap company. Dana Inv Advsrs invested in 0.34% or 138,913 shares. (NASDAQ:ESPR) from a hold rating to a buy rating in a report issued on Sunday. Two Sigma Limited Liability Co owns 0.06% invested in Esperion Therapeutics, Inc. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since December 14, 2016 and is uptrending. Vanguard Gp Inc holds 0% or 756,224 shares in its portfolio. Discovery Mgmt Llc Ct reported 965,059 shares or 1.08% of all its holdings.

Prince Harry and Meghan Markle to marry 19 May
On Friday, the palace officially confirmed that Harry and Meghan will walk down the aisle on May 19, 2018 . They will be married in St George's Chapel at Windsor Castle , just west of London.


Stuart Weisbrod increased its stake in Esperion Therapeutics Inc Ne (ESPR) by 33.33% based on its latest 2017Q2 regulatory filing with the SEC. (NASDAQ:ESPR) for 1.51 million shares. Northland Securities reissued a buy rating and issued a $72.00 price target on shares of Esperion Therapeutics in a report on Friday, November 10th. Therefore 61% are positive. Needham & Company LLC now has $81.00 price target on the biopharmaceutical company's stock, up from their prior price target of $72.00. Barclays Capital maintained Esperion Therapeutics, Inc.

Although it is helpful to understand the rate of growth each year relative to today's value, it may be more insightful to determine the rate at which the company is growing on average every year. The firm has "Strong Buy" rating given on Monday, March 20 by Needham. Chardan Capital Markets maintained it with "Sell" rating and $40 target in Monday, July 27 report. Finally, Chardan Capital upped their target price on Esperion Therapeutics from $20.00 to $75.00 and gave the stock a "neutral" rating in a research note on Wednesday, December 6th. As per Wednesday, March 9, the company rating was maintained by JMP Securities. Chardan Capital Markets has "Sell" rating and $29 target. The firm has "Hold" rating by Keefe Bruyette & Woods given on Tuesday, October 17. Oppenheimer downgraded ONEOK, Inc. (NASDAQ:ESPR) on Wednesday, June 29 to "Neutral" rating. "Today" on August 08, 2017. Hwg Holdings Lp sold 3,716 shares as Svb Finl Group (SIVB)'s stock declined 4.82%. Shares for $616,644 were sold by Newlands William A on Monday, October 9. Cox Philip C sold $552,793 worth of stock or 3,024 shares.

Investors sentiment increased to 1.67 in Q2 2017. Its down 0.02, from 1.16 in 2017Q1. Finally, Meditor Group Ltd lifted its holdings in shares of Esperion Therapeutics by 305.5% during the 3rd quarter. 108 funds opened positions while 221 raised stakes. Assetmark has 0.04% invested in Kayne Anderson MLP Investment Company (NYSE:KYN) for 168,350 shares. 18 are held by Tortoise Invest Ltd Liability Co. (NASDAQ:ESPR). California State Teachers Retirement holds 26,416 shares. 31,783 are owned by Retail Bank Of America Corp De. Bard Associate Incorporated has invested 0.26% in Kayne Anderson MLP Investment Company (NYSE:KYN). Sg Americas Secs Ltd Limited Liability Company invested in 0.04% or 23,800 shares. State Street holds 1.51 million shares. Aisling Lc holds 6.64% or 837,125 shares in its portfolio. The rating was downgraded by Zacks to "Hold" on Friday, September 4. (NYSE:STZ) for 6,307 shares. Art Advisors Limited Co owns 55,460 shares. Cantab Capital Llp holds 4,186 shares. (NASDAQ:ESPR). Jpmorgan Chase Communications owns 0% invested in Esperion Therapeutics, Inc. Therefore 24% are positive. Interactive Brokers Group had 16 analyst reports since September 1, 2015 according to SRatingsIntel. Esperion Therapeutics has a consensus rating of Buy and an average price target of $60.85. The company was maintained on Thursday, February 25 by Stifel Nicolaus. FinnCap maintained Constellation Brands, Inc. (NYSE:OKE) on Friday, January 22 to "Perform" rating. Buckingham Research initiated the shares of IBKR in report on Thursday, May 12 with "Neutral" rating. The rating was upgraded by Needham to "Buy" on Monday, August 10. The stock has "Buy" rating by Pivotal Research on Thursday, June 29. UBS has "Buy" rating and $59 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Comments